We read with great interest the article by Henke et al 1 describing that erythropoietin (Epo) treatment might adversely affect prognosis of head and neck cancer patients if cancer cells express erythropoietin receptors (EpoR).
No takes yet. Share an insight, caveat, or question.
Ragione et al. (2007) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: